Ruxolitinib deuterated

Drug Profile

Ruxolitinib deuterated

Alternative Names: CTP-543; deuterated ruxolitinib; Deuterium modified ruxolitinib - Concert Pharmaceuticals

Latest Information Update: 09 Mar 2017

Price : $50

At a glance

  • Originator Concert Pharmaceuticals
  • Class 2 ring heterocyclic compounds; Cyclopentanes; Nitriles; Organic deuterium compounds; Pyrazoles; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alopecia areata

Most Recent Events

  • 06 Mar 2017 Pharmacodynamics data from a phase I trial in Alopecia areata released by Concert Pharmaceuticals
  • 04 Mar 2017 Pharmacokinetics and adverse events data from a phase I trial in Alopecia areata presented at the the American Academy of Dermatology’s Annual Meeting (AAD-2017)
  • 04 Mar 2017 Concert plans a phase IIa trial for Alopecia areata
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top